You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Ibritumomab Tiuxetan in Lymphoma

ID: 6-17 Nov 2013
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
Hematology Disease Site Group

Patient Population

Adult patients with non-Hodgkin’s lymphoma of any type, at any stage of disease, and for any level of performance status.

Research Question(s)

In patients with lymphoma of any type or stage:

  1. What is the role of yttrium-90 (90Y) ibritumomab tiuxetan? Outcomes of interest include survival, quality of life, time-to-progression, response duration, response rate, and toxicity.
  2. Which patients are more or less likely to benefit from treatment with 90Y-ibritumomab tiuxetan?
  3. Is performance of imaging or dosimetry required for therapy to be safe and effective?
pdf download Full Report (PDF) (866.95 KB)